23/07/2010 (Agence Europe) - After review of modified-release oral opioids of the WHO level III scale, the European Medicines Agency (EMEA) concluded that these products remain very useful in managing pain, but require harmonised review of warnings concerning the risk of interaction with alcohol. The risk is the highest for products containing polymethracrylate-triethylcitrate, and the EMEA recommends that the Commission suspend the authorisation for the marketing of these medicines until...